Beam Therapeutics Inc. (NASDAQ:BEAM) Stock Now Rated “Moderate Buy” by Wall Street Analysts

Shares of Beam Therapeutics Inc. (NASDAQ:BEAM) have received an average rating of “Moderate Buy” from the twelve ratings firms that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, eight have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $47.00.

A number of brokerages recently weighed in on BEAM. Wall Street Zen lowered shares of Beam Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, October 31st. William Blair raised shares of Beam Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 23rd. Wedbush lifted their price target on shares of Beam Therapeutics from $28.00 to $30.00 and gave the company an “outperform” rating in a research note on Wednesday. Bank of America reiterated a “buy” rating and issued a $47.00 price target on shares of Beam Therapeutics in a report on Wednesday, July 8th. Finally, HC Wainwright reissued a “buy” rating on shares of Beam Therapeutics in a research note on Tuesday, October 27th.

Insider Transactions at Beam Therapeutics

In other news, CEO John Evans sold 25,000 shares of the business’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $23.57, for a total value of $589,250.00. Following the completion of the sale, the chief executive officer owned 1,047,205 shares in the company, valued at approximately $24,682,621.85. The trade was a 2.33% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 3.80% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Beam Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of BEAM. Versant Capital Management Inc boosted its stake in Beam Therapeutics by 123.6% in the third quarter. Versant Capital Management Inc now owns 1,239 shares of the company’s stock valued at $30,000 after acquiring an additional 685 shares in the last quarter. Northwestern Mutual Wealth Management Co. acquired a new position in shares of Beam Therapeutics during the second quarter worth $43,000. Hollencrest Capital Management acquired a new position in shares of Beam Therapeutics during the first quarter worth $43,000. Fulcrum Asset Management LLP acquired a new position in shares of Beam Therapeutics during the third quarter worth $51,000. Finally, Nykredit A S purchased a new stake in shares of Beam Therapeutics during the 2nd quarter valued at $75,000. 99.68% of the stock is currently owned by institutional investors.

Trending Headlines about Beam Therapeutics

Here are the key news stories impacting Beam Therapeutics this week:

• Positive Sentiment: Beam said it will present updated BEACON Phase 1/2 data on risto-cel for sickle cell disease at the American Society of Hematology meeting. The company highlighted early, sustained improvements in patients’ reported physical function, pain, fatigue, and well-being, and said a U.S. BLA submission could come as early as year-end 2026. Company announcement
• Positive Sentiment: Wedbush raised its price target to $30 from $28 and reiterated an Outperform rating, signaling a more favorable view of the stock’s prospects. Wedbush price-target update
• Neutral Sentiment: Canaccord trimmed its target to $78 from $79 but maintained a Buy rating, leaving a broadly bullish recommendation despite the small reduction. Canaccord analyst ratings
• Neutral Sentiment: Beam also outlined plans to start a Phase 1/2 trial of BEAM-304 for phenylketonuria in early 2027, adding a future development milestone but not an immediate clinical result. BEAM-304 trial plans
• Negative Sentiment: Third-quarter results missed expectations: Beam reported a loss of $1.28 per share versus the $1.17 consensus, while revenue was $0.31 million against estimates of $8.75 million and fell 96.8% year over year. Quarterly results

Beam Therapeutics Stock Performance

Beam Therapeutics stock opened at $27.79 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 14.57 and a quick ratio of 14.57. The firm has a market capitalization of $2.87 billion, a P/E ratio of -26.72 and a beta of 2.23. Beam Therapeutics has a 1-year low of $20.23 and a 1-year high of $38.26. The company’s 50-day moving average is $25.75 and its 200 day moving average is $28.08.

Beam Therapeutics (NASDAQ:BEAM) last announced its earnings results on Tuesday, November 3rd. The company reported ($1.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.11). The business had revenue of $0.31 million for the quarter, compared to analysts’ expectations of $8.75 million. Beam Therapeutics had a negative net margin of 73.04% and a negative return on equity of 31.32%. The firm’s quarterly revenue was down 96.8% on a year-over-year basis. During the same quarter last year, the firm earned ($1.10) EPS. Research analysts forecast that Beam Therapeutics will post -4.49 EPS for the current year.

Beam Therapeutics Company Profile

Beam Therapeutics Inc is a biotechnology company developing precision genetic medicines for patients with serious diseases. The company’s platform uses base editing, a form of gene editing designed to make targeted changes to individual DNA letters without creating double-strand breaks. Beam is also advancing related editing technologies and delivery systems intended to improve the precision and effectiveness of genetic treatments.

Beam’s pipeline includes investigational programs for diseases such as sickle cell disease, beta thalassemia, alpha-1 antitrypsin deficiency and glycogen storage disease type Ia.